Alcon, Inc. engages in the development, manufacture, and marketing of market surgical equipment and devices, pharmaceutical eye drops, and consumer vision care products to treat eye diseases and disorders. It operates through the following segments: Surgical and Vision Care. The Surgical segment offers implantable products, consumables and equipment for use in surgical procedures to address cataracts, vitreoretinal conditions, refractive errors, and glaucoma. The Vision Care segment comprises daily disposable, reusable and color-enhancing contact lenses, as well as portfolio of ocular health products, including over-the-counter products for dry eye, contact lens care, and ocular allergies, as well as ocular vitamins and redness relievers. The company was founded by Mr. Robert Alexander and Mr. William Conner on 1945 and is headquartered in Geneva, Switzerland.

Alcon Research Ltd., a subsidiary of Nestl�� SA, is a company headquartered in Huntington, WV, that manufactures optical goods.

ClarVista Medical is a developer of innovative products to treat challenging ophthalmic conditions. In 2012 and in conjunction with series A financing, ClarVista was spun out from Prospex Medical, a medical device incubator, to pursue the development of the HARMONI™ IOL. Between 2012 and 2014, the company developed the first generation HARMONI™ system, conducted thorough first-in-human clinical study and developed a broad portfolio of intellectual property. In 2015 the company closed on a series B financing of $14M which will be used to develop the second generation HAROMONI™ system, conduct a larger feasibility clinical trial and obtain key regulatory approvals including CE mark and US IDE.

IntraLase Corporation is a leader in the first step of LASIK surgery, the most common means of surgical vision correction. They design, develop and market a laser, related software and disposable devices used to create a cut of tissue across the cornea of a patient’s eye, or a corneal flap, which is the first step in LASIK surgery. Their advanced laser technology improves the safety, precision and visual acuity of LASIK surgery by providing a computer-controlled laser solution as an alternative to the traditional method of creating the corneal flap using a hand-held mechanical, metal-bladed device called a microkeratome. They believe their product offering will become the new standard of care for corneal flap creation. As of April 2, 2007, IntraLase Corp. was acquired by Advanced Medical Optics Inc.

LENSAR offers femtosecond laser technology for refractive cataract surgery, continues to focus on astigmatism, and supports the pursuit of possible results for patients with its Streamline® IV system upgrade. Unique to the LENSAR Laser System, Streamline IV includes various enhancements that offer cataract surgeons advanced adaptation and customization for treatment planning and other essential steps of the cataract surgery procedure with the highest levels of precision, accuracy, and efficiency. To help surgeons confidently manage astigmatism and optimize refractive outcomes for both toric IOLs and arcuate incisions, the LENSAR Laser with Streamline IV has incorporated extreme treatment planning insights. This includes quick and easy patient docking, as well as superior imaging capabilities with LENSAR’s proprietary Augmented Reality™ 3-D model. This technology facilitates enhanced procedure outcomes by adapting individualized treatment plans including precise laser delivery and efficient lens fragmentation that can reduce, and potentially eliminate, the amount of ultrasonic energy delivered into the eye. Additionally, the IntelliAxis Refractive Capsulorhexis® feature provides another dimension of accuracy with biomechanically stable, steep axis markings that help guide precise toric IOL alignment. The marks remain visible postoperatively to help identify any rotation and guide the realignment of the toric IOL to its optimal position. IntelliAxis Refractive Capsulorhexis also incorporates the wireless transfer of preoperative diagnostics from the Cassini® Corneal Shape Analyzer and Pentacam® to help eliminate transcription errors, save time, and guide more confident astigmatism correction. Iris registration further contributes to the system’s accuracy by comparing a pre-op image taken while the eye is docked and adaptively compensates for cyclo rotation for confidence incision placement. LENSAR has recently expanded the platform’s capabilities to include the creation of micro radial incisions that allow surgeons to treat additional corneal conditions post-cataract surgery and support presbyopia inlay procedures. Building on the strength of LENSAR’s foundational femtosecond cataract laser platform, the LENSAR Laser with Streamline IV simplifies practice and surgical workflows while also revolutionizing a surgeon’s ability to deliver optimal outcomes for astigmatic patients.

Capsulaser is a laser technology company that creates tear-resistant capsulotomy during cataract surgery. It provides a cost and time-effective solution to create the ideal capsulotomy. The company's laser energy is delivered in a continuous manner rather than a pulsed beam which can create tissue bridges. Capsulaser was founded in 2016 in Livermore, CA.

OptiMedica Corporation is a Silicon Valley-based global ophthalmic device company dedicated to developing performance-driven technologies that improve patient outcomes. The company was founded in 2004 with the vision of bringing innovative new technologies to ophthalmologists and transforming existing standards of care. Since its founding, OptiMedica has been developing a reproducible, noninvasive technique to replace the inconsistent manual steps in cataract surgery with femtosecond laser technology. The system has been designed to deliver new levels of precision, control, performance, and efficacy to cataract surgeons and their patients. OptiMedica has completed clinical trials of its Catalysâ„¢ Precision Laser System, with very promising results reported across these measures. While the Catalys Precision Laser System is not currently for sale in the United States, OptiMedica expects to launch the system in U.S. and international markets in 2011.

Provides information technology and janitorial services

Consiglio Nazionale delle Ricerche is the largest public research facility in Italy. Founded in 1923, it has worked in the past as a government consultant on research and as a funding fund for university research grants. Since 1989 the CNR is a research institution, with the mission of carrying out research projects, promoting innovation and competitiveness of the national industrial system, the internationalization of the national research system, and providing technologies and solutions to emerging needs in the public and private sectors. . Objectives that are achieved through a wealth of human resources that has over 8000 employees, half of which is represented by researchers and technologists. About 4,000 young researchers are involved in post-doctoral research activities in the laboratories of the Institute, while an important contribution comes from collaborations, including international ones, with researchers from universities and companies, thus strengthening the national research system.

D.O.R.C. Dutch Ophthalmic Research Center (International) BV engages in the development and manufacture of ophthalmic surgical disposables, instruments and units. It offers offers precision disposable and re-usable instruments, surgical liquids and surgical machinery that is used for vitreoretinal and cataract procedures. The firm serves surgical centers, hospitals and physicians. The company was founded by Ger Vijfvinkel in 1983 and is headquartered in Zuidland, the Netherlands.

Inokang Medical Technology (Suzhou) Co., Ltd., established on 2014-06-18, Business scope includes medical devices,Technology research and development of medical polymer materials and products,technical consulting,Technical Services,technology transfer;Medical device production,Sales,And provide related after-sales service,Medical devices and their parts(Medical device management)Wholesale,import and export,commission agent(except auction),and provide related services;Self-operated and agent import and export business of the above commodities and technologies.(Items subject to approval by law,Business activities can only be carried out after approval by relevant departments)

The Brien Holden Vision Institute (BHVI) is an Australian nonprofit non-governmental organization with an international focus on eye care research and vision care delivery. Formerly the Institute for Eye Research, in 2010 it was renamed in recognition of co-founder Brien Holden, a 1997 recipient of the Medal of the Order of Australia for his contributions to eye care research.

Moria SA develops and manufactures equipment for ophthalmic surgery. It designs and sells precision instruments and equipment such as metal containers for surgical instruments, tools for refractive and corneal surgeries, and single-use and hand-held instruments for all types of surgery. It also offers a range of instruments for use in lamellar surgery. The company was founded in 1820 and is headquartered in Antony, France.

LensGen is an ophthalmic medical device company that has developed a biomimetic, curvature changing fluid-optic intraocular lens designed for the treatment of cataracts and presbyopia. It offers Juvene™ which is designed to fit inside the same location as the natural human lens and adjusts dioptric power on demand through curvature change by using the same tiny muscle contractions that occur within the eye.

The Nanjing General Hospital of People's Liberation Army (NGH; Chinese: 中国人民解放军南京总医院), formerly Nanjing General Hospital of Nanjing Military Command (Chinese: 中国人民解放军南京军区南京总医院), or Nanjing General Hospital, The Military General Hospital, is also known as Jinling Hospital (formally Jinling Hospital of the Medical School of Nanjing University) which used to be Central Hospital. NGH is located at 305 Zhongshan East Road, Nanjing, Jiangsu Province, China. It is a large comprehensive teaching hospital integrating medical services with teaching and research.

Shanghai Tingyimei Technology Co., Ltd., established on 2019-08-02, The scope of business includes engaging in biotechnology(genetically modified organism,Except human stem cell genetic diagnosis),electronic technology,Technology development in the professional field of computer information technology,technology transfer,technical consulting,Technical Services,Medical device management,Electrical Equipment,Glasses and Accessories,cosmetic,Sales of daily necessities,Exhibition display service,business inquiries,e-commerce(Not allowed to engage in value-added telecommunications,Financial services),Engaged in the import and export of goods and technology. [Items subject to approval by law,Business activities can only be carried out after approval by relevant departments]

Novartis AG is a holding company, which engages in the development, manufacture, and marketing of healthcare products. It operates through the following segments: Innovative Medicines, Sandoz, and Corporate. The Innovative Medicines segment researches, develops, manufactures, distributes and sells patented pharmaceuticals, and is composed of two business units: Novartis Oncology and Novartis Pharmaceuticals. The Sandoz segment develops, manufactures and markets finished dosage form medicines as well as intermediary products, including active pharmaceutical ingredients. The Corporate segment refers to group management and central services. The company was founded on February 29, 1996 and is headquartered in Basel, Switzerland.